유럽 연합 - 몰타어 - EMA (European Medicines Agency)

pharmaswiss ceska republika s.r.o - pegaptanib - deġenerazzjoni makulari mxarrba - oftalmoloġiċi - macugen huwa indikat għat-trattament ta 'deġenerazzjoni makulari neovaskulari (mxarrba) relatata ma' l-età (amd).

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosoppressanti - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - radjofarmaċewtiċi dijanjostiċi - dan il-prodott mediċinali huwa għal użu dijanjostiku biss. wara l-radjutikkettar ma ' gallju (68ga) chloride, is-soluzzjoni tal-gallju (68ga) edotreotide miksuba huwa indikat għall-positron emission tomography (pet) tal-immaġini tal-somatostatin tar-riċettur tal-espressjoni żejda f'pazjenti adulti b'ikkonfermat jew suspettat differenzjat tajjeb gastro-enteropancreatic newroendokrinika tumuri (gep-net) għal lokalizzazzjoni primarja tumuri u l-metastasi.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drogi użati fid-dijabete - dijabete mellitus fejn huwa meħtieġ it-trattament bl-insulina. insuman rapid huwa wkoll adattat għall-kura ta 'koma ipergliċemika u ketoaċidożi, kif ukoll għall-kisba ta' stabilizzazzjoni minn qabel, intra u wara l-operazzjoni f'pazjenti bid-dijabete mellitus.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

mallinckrodt deutschland gmbh - gadoversetamide - immaġni tar-reżonanza manjetika - midja ta 'kuntrast - dan il-prodott mediċinali huwa għal użu dijanjostiku biss. optimark hu indikat għall-użu mal-immaġni tar-reżonanza manjetika (mri) tas-sistema nervuża ċentrali (cns) u l-fwied. jipprovdi titjib tal-kuntrast u jiffaċilita l-viżwalizzazzjoni u jgħin fil-karatterizzazzjoni tal-leżjonijiet fokali u strutturi anormali fis-cns u fil-fwied f'pazjenti b'magħrufa jew issuspettata patoloġija.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

dendreon uk ltd - awtologi periferali-ċelluli tad-demm lewkoċciti mononukleari inklużi minimu ta ' 50 miljun cd54 + għaċ-ċelloli awtoloġiċi attivat b'fattur fosfataŻi aċidu prostatic granulocyte-macrophage-istimulazzjoni tal-kolonja - neoplasmi prostatiċi - immunostimulanti oħrajn - provenge huwa indikat għat-trattament ta 'kanċer tal-prostata mhux sintomatiku sintomatiku jew sintomatiku metastatiku (mhux vixxerali) f'adulti maskili li fihom il-kemjoterapija għadha mhix indikata klinikament.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibatteriċi għal użu sistemiku, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi. l-użu xieraq ta ' sustanzi antibatteriċi.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - neoplasmi prostatiċi - radjofarmaċewtiċi terapewtiċi - xofigo huwa indikat għat-trattament ta 'adulti b'kanċer tal-prostata li jiflaħ għall-kastrazzjoni, metastasi sintomatika fl-għadam u l-ebda metastasi viscerali magħrufa.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

scipharm sàrl - treprostinil sodium - pressjoni għolja, pulmonari - aġenti antitrombotiċi - treatment of adult patients with who functional class (fc) iii or iv and:inoperable chronic thromboembolic pulmonary hypertension (cteph), orpersistent or recurrent cteph after surgical treatmentto improve exercise capacity.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - drogi oħra tas-sistema nervuża - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.